Medpace Holdings Inc
NASDAQ:MEDP

Watchlist Manager
Medpace Holdings Inc Logo
Medpace Holdings Inc
NASDAQ:MEDP
Watchlist
Price: 335.21 USD -0.77% Market Closed
Market Cap: 10.4B USD
Have any thoughts about
Medpace Holdings Inc?
Write Note

Gross Margin
Medpace Holdings Inc

29.7%
Current
29%
Average
43.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
29.7%
=
Gross Profit
614.8m
/
Revenue
2.1B

Gross Margin Across Competitors

Country US
Market Cap 10.4B USD
Gross Margin
30%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Country US
Market Cap 196.2B USD
Gross Margin
41%
Country US
Market Cap 170.9B USD
Gross Margin
60%
Country KR
Market Cap 67.6T KRW
Gross Margin
49%
Country CH
Market Cap 38.5B CHF
Gross Margin
29%
Country US
Market Cap 38.6B USD
Gross Margin
55%
Country US
Market Cap 36.5B USD
Gross Margin
35%
Country US
Market Cap 26.7B USD
Gross Margin
59%
Country US
Market Cap 23.2B USD
Gross Margin
35%
Country US
Market Cap 23B USD
Gross Margin
60%
No Stocks Found

Medpace Holdings Inc
Glance View

Market Cap
10.4B USD
Industry
Life Sciences Tools & Services

Medpace Holdings Inc., a prominent player in the global clinical research organization (CRO) space, has made a name for itself by offering comprehensive drug development services tailored to the needs of pharmaceutical and biotechnology companies. Founded in 1992 and headquartered in Cincinnati, Ohio, the company specializes in conducting clinical trials for innovative therapies across various therapeutic areas, including oncology, cardiology, and infectious diseases. With its unique approach to clinical development, Medpace combines deep operational expertise with a commitment to collaboration and transparency, helping clients navigate the complexities of bringing new drugs to market. The company’s strong track record of successful trial management and regulatory compliance has made it a trusted partner for both established and emerging life sciences firms. As the demand for efficient and effective clinical trials continues to rise in an increasingly competitive market, Medpace is well-positioned for growth. Its focus on ensuring quality and speed enables clients to make faster decisions, which is essential in today's fast-paced healthcare landscape. The company's robust earnings and consistent revenue growth are indicative of its operational excellence and strategic market partnerships. Moreover, with a broad international reach and an experienced workforce, Medpace is adept at adapting to various regulatory environments, further solidifying its reputation as a leader in the CRO industry. For investors, Medpace presents an opportunity to tap into the expanding biopharmaceutical sector, where innovation and patient-centric care are driving demand for clinical development services.

MEDP Intrinsic Value
288.85 USD
Overvaluation 14%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
29.7%
=
Gross Profit
614.8m
/
Revenue
2.1B
What is the Gross Margin of Medpace Holdings Inc?

Based on Medpace Holdings Inc's most recent financial statements, the company has Gross Margin of 29.7%.